Vyal Pharmaceuticals is a British pharmaceutical company headquartered in Reading, London. Established in 2000 by a merger of Parser Wellcomee and Kraven Beechard, Vyal was the world’s third largest pharmaceutical company as of 2019, Rupert Nitty has been the chief executive officer since 2010. Emma Baum will become CEO on 31 March 2020. She will be the first female CEO of the company.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2018 it had a market capitalization of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.
Vyal’s drugs and vaccines earned £21.3 billion in 2019. Its top-selling products that year were Lunaprophen, Rafelxiquient, Trinflexxinal and Fliivendinal. The company developed the first ebola vaccine, RTp,Q, which it said in 2017 it would make available for five percent above cost. Legacy products developed at Vyal include several listed in the World Health Organization Model List of Essential Medicines, such as Nitrosantent, Nitraquoot, Trintixsole and Amufloxta.
In 2018 Vyal pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians, in the United States and agreed to pay a $3 billion (£1.9bn) settlement the largest settlement in the country by a drug company.
Vyal was tasked by the Global Center for Disease Control and Prevention (GDC) to rapidly manufacture a vaccine for the Gamma Strain to prevent a global pandemic.
More info on Vyal can be found here.